Recombinant Anti-FEN1 antibody [EPR4460(2)] (ab109132)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR4460(2)] to FEN1
- Suitable for: WB, IHC-P
- Reacts with: Human
Related conjugates and formulations
Overview
-
Product name
Anti-FEN1 antibody [EPR4460(2)]
See all FEN1 primary antibodies -
Description
Rabbit monoclonal [EPR4460(2)] to FEN1 -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details
Unsuitable for: Flow Cyt,ICC/IF or IP -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
(Peptide available asab95382) -
Positive control
- Jurkat, HeLa, Y79, and Daudi cell lysates, Human testis, Human tonsil, and Human urothelial carcinoma tissues
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.20
Preservative: 0.05% Sodium azide
Constituents: 0.1% BSA, 40% Glycerol (glycerin, glycerine), 9.85% Tris glycine, 50% Tissue culture supernatant -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR4460(2) -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Immunizing Peptide (Blocking)
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab109132 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/1000 - 1/10000. Detects a band of approximately 42 kDa (predicted molecular weight: 42 kDa).Can be blocked with Recombinant Human FEN1 protein (ab95382).
|
|
IHC-P |
1/500 - 1/750. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
|
Notes |
---|
WB
1/1000 - 1/10000. Detects a band of approximately 42 kDa (predicted molecular weight: 42 kDa).Can be blocked with Recombinant Human FEN1 protein (ab95382). |
IHC-P
1/500 - 1/750. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. |
Target
-
Function
Structure-specific nuclease with 5'-flap endonuclease and 5'-3' exonuclease activities involved in DNA replication and repair. During DNA replication, cleaves the 5'-overhanging flap structure that is generated by displacement synthesis when DNA polymerase encounters the 5'-end of a downstream Okazaki fragment. It enters the flap from the 5'-end and then tracks to cleave the flap base, leaving a nick for ligation. Also involved in the long patch base excision repair (LP-BER) pathway, by cleaving within the apurinic/apyrimidinic (AP) site-terminated flap. Acts as a genome stabilization factor that prevents flaps from equilibrating into structurs that lead to duplications and deletions. Also possesses 5'-3' exonuclease activity on nicked or gapped double-stranded DNA, and exhibits RNase H activity. Also involved in replication and repair of rDNA and in repairing mitochondrial DNA. -
Sequence similarities
Belongs to the XPG/RAD2 endonuclease family. FEN1 subfamily. -
Post-translational
modificationsAcetylated by EP300. Acetylation inhibits both endonuclease and exonuclease activity. Acetylation also reduces DNA-binding activity but does not affect interaction with PCNA or EP300.
Phosphorylation upon DNA damage induces relocalization to the nuclear plasma. Phosphorylation at Ser-187 by CDK2 occurs during late S-phase and results in dissociation from PCNA.
Methylation at Arg-192 by PRMT5 impedes Ser-187 phosphorylation and increases interaction with PCNA. -
Cellular localization
Nucleus > nucleolus. Nucleus > nucleoplasm. Mitochondrion. Resides mostly in the nucleoli and relocalizes to the nucleoplasm upon DNA damage. - Information by UniProt
-
Database links
- Entrez Gene: 2237 Human
- Entrez Gene: 14156 Mouse
- Entrez Gene: 84490 Rat
- Omim: 600393 Human
- SwissProt: P39748 Human
- SwissProt: P39749 Mouse
- SwissProt: Q5XIP6 Rat
- SwissProt: Q9JHW7 Rat
see all -
Alternative names
- DNase IV antibody
- FEN-1 antibody
- FEN1 antibody
see all
Images
-
All lanes : Anti-FEN1 antibody [EPR4460(2)] (ab109132) at 1/1000 dilution
Lane 1 : Jurkat cell lysate
Lane 2 : HeLa cell lysate
Lane 3 : Y79 cell lysate
Lane 4 : Daudi cell lysate
Lysates/proteins at 10 µg per lane.
Predicted band size: 42 kDa -
Immunohistochemical analysis of paraffin-embedded Human testis tissue using ab109132 at a dilution of 1/500.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Human tonsil tissue using ab109132 at a dilution of 1/500.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
-
Immunohistochemical analysis of paraffin-embedded Human urothelial carcinoma tissue using ab109132 at a dilution of 1/500.
Perform heat mediated antigen retrieval before commencing with IHC staining protocol.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (10)
ab109132 has been referenced in 10 publications.
- Gerdtsson AS et al. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors. Haematologica 108:1092-1104 (2023). PubMed: 36519324
- Zhou J et al. Proteomic Analyses Identify Differentially Expressed Proteins and Pathways Between Low-Risk and High-Risk Subtypes of Early-Stage Lung Adenocarcinoma and Their Prognostic Impacts. Mol Cell Proteomics 20:100015 (2021). PubMed: 33508502
- Cong K et al. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell 81:3128-3144.e7 (2021). PubMed: 34216544
- Huang W et al. Jianpi-yangwei decoction inhibits DNA damage repair in the drug resistance of gastric cancer by reducing FEN1 expression. BMC Complement Med Ther 20:196 (2020). PubMed: 32586310
- Pu J et al. IGF2BP2 Promotes Liver Cancer Growth Through an m6A-FEN1-Dependent Mechanism. Front Oncol 10:578816 (2020). PubMed: 33224879
- Guo Y & Luo S miR-140-5p inhibits cervical cancer cell phenotypes via downregulating FEN1 to halt the cell cycle. Mol Med Rep 22:4919-4930 (2020). PubMed: 33173950
- Isohookana J et al. Proteins of the retinoblastoma pathway, FEN1 and MGMT are novel potential prognostic biomarkers in pancreatic adenocarcinoma. Pathol Res Pract 214:840-847 (2018). IHC-P ; Human . PubMed: 29735403
- Ma S et al. LncRNA BANCR promotes tumorigenesis and enhances adriamycin resistance in colorectal cancer. Aging (Albany NY) 10:2062-2078 (2018). PubMed: 30144787
- Ward TA et al. Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes. PLoS One 12:e0179278 (2017). WB ; Human . PubMed: 28628639
- Exell JC et al. Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site. Nat Chem Biol 12:815-21 (2016). WB ; Human . PubMed: 27526030